Announcements Trials
Browse Landscape

Status

Completed 3Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 68Observational 4

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Myeloid 1

Conditions

Multiple Myeloma 7Recurrence 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Mantle-Cell 3Lymphoma, Follicular 2Lymphoma 2Tumor Lysis Syndrome 1Thromboembolism 1Teratogenesis 1Sleepiness 1Seizures 1Renal Insufficiency 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Neoplasms, Second Primary 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Lung Diseases, Interstitial 1Infections 1Hypothyroidism 1Hypotension, Orthostatic 1Hypersensitivity 1Hemorrhage 1Heart Failure 1Fatigue 1Dizziness 1Digestive System Diseases 1Coronary Artery Disease 1Confusion 1

Interventions

Surgical Procedures, Operative 7Liver Transplantation 5Lenalidomide 4Blood Specimen Collection 4pomalidomide 3Neoadjuvant Therapy 3Liquid Biopsy 3gilteritinib 2Therapeutics 2Rituximab 2Proteasome Inhibitors 2Observation 2Mohs Surgery 2Mitomycin 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Immunoconjugates 2High-Throughput Nucleotide Sequencing 2Fluorouracil 2Drug Therapy 2DNA, Mitochondrial 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2Antibodies, Monoclonal 2Antibodies, Bispecific 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1romidepsin 1nedaplatin 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Recurrence × Lenalidomide × Clear all
NCT06163040 2025-07-31

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb

Completed
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04036448 2025-03-11

RevlimidPMS

Celgene

Completed
28 enrolled
LymphoidMyeloid

Lymphoma, Follicular, Myelodysplastic Syndromes, Recurrence, Lymphoma, Mantle-Cell

NCT03647124 2025-03-04

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Celgene

Completed
105 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

NCT04109872 2020-02-05

Lenalidomide Observational Study in Patients With Mantle Lymphoma in Relapse/Refraction. Spanish Programme RRMCL Results.

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Unknown
25 enrolled
Lymphoid

Recurrence, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡